Drug Trial Radar · NCT06181435
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
589
Actual
Start
Dec 21, 2023
Primary completion
Nov 25, 2025
Study completion Mar 12, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).
Conditions
- Dermatitis Atopic
Interventions
AmlitelimabDrug
Pharmaceutical form: Injection solution Route of administration: SC injection
PlaceboDrug
Pharmaceutical form: Injection solution Route of administration: SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24
- EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24Time frame: Week 24
- US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24
Locations
142 sites in 16 countries. Site status is shown where the registry gives one.
Center for Dermatology and Plastic Surgery- Site Number : 8401119
Scottsdale, Arizona
Eclipse Clinical Research- Site Number : 8401158
Tucson, Arizona
Torrance Clinical Research- Site Number : 8401027
Lomita, California
Dermatology Research Associates - Los Angeles- Site Number : 8401092
Los Angeles, California
Allergy & Asthma Associates of Southern California - Mission Viejo- Site Number : 8401079
Mission Viejo, California
Cura Clinical Research - Oxnard- Site Number : 8401142
Oxnard, California
Clinical Science Institute- Site Number : 8401028
Santa Monica, California
University of Connecticut Health Center- Site Number : 8401115
Farmington, Connecticut
Pediatric Skin Research- Site Number : 8401198
Coral Gables, Florida
Skin Care Research - Hollywood- Site Number : 8401071
Hollywood, Florida
Savin Medical Group - Miami- Site Number : 8401085
Miami, Florida
Anchor Medical Research- Site Number : 8401300
Miami, Florida
Accel Research - Nona Pediatric Center- Site Number : 8401081
Orlando, Florida
Nuline Clinical Trial Center- Site Number : 8401161
Pompano Beach, Florida
Clinical Research Trials of Florida- Site Number : 8401023
Tampa, Florida
AllerVie Clinical Research - Columbus- Site Number : 8401104
Columbus, Georgia
First Georgia Physician Group- Site Number : 8401190
Fayetteville, Georgia
Access Dermatology- Site Number : 8401296
Bowling Green, Kentucky
MedPharmics - Covington- Site Number : 8401137
Covington, Louisiana
Care Access Research - Marriottsville- Site Number : 8401126
Marriottsville, Maryland
Tufts Medical Center Site Number : 8401201
Boston, Massachusetts
University Of Mississippi Medical Center- Site Number : 8401184
Jackson, Mississippi
Care Access - Hoboken- Site Number : 8401132
Hoboken, New Jersey
University of New Mexico Comprehensive Cancer Center- Site Number : 8401263
Albuquerque, New Mexico
OmeraNY- Site Number : 8401156
Brooklyn, New York
Equity Medical- Site Number : 8401239
New York, New York
Montefiore Medical Center - Moses Campus- Site Number : 8401150
The Bronx, New York
Red River Research Partners- Site Number : 8401196
Fargo, North Dakota
Bexley Dermatology Research- Site Number : 8401051
Bexley, Ohio
Velocity Clinical Research - Springdale- Site Number : 8401153
Cincinnati, Ohio
Dermatology Associates of Plymouth Meeting- Site Number : 8401147
Plymouth Meeting, Pennsylvania
PEAK Research- Site Number : 8401083
Upper Saint Clair, Pennsylvania
Columbia Dermatology & Aesthetics- Site Number : 8401166
Columbia, South Carolina
Health Concepts- Site Number : 8401059
Rapid City, South Dakota
Arlington Research Center- Site Number : 8401248
Arlington, Texas
Derm Texas- Site Number : 8401217
Dallas, Texas
Center for Clinical Studies - Houston - Binz Street- Site Number : 8401063
Houston, Texas
Prolato Clinical Research Center- Site Number : 8401209
Houston, Texas
Sienna Dermatology- Site Number : 8401148
Missouri City, Texas
Progressive Clinical Research - San Antonio- Site Number : 8401016
San Antonio, Texas
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.